NXL — Nexalin Technology Share News
0.000.00%
Last trade - 00:00- $2.03m
- $1.03m
- $0.30m
Brief: Nexalin Technology Prices $5 Million Public Offering
Brief: Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design
Brief: Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia
Brief: Nexalin Technology Inc May Offer, Sell Up To $50 Mln Of Common Stock From Time To Time In One Or More Offerings
Brief: Nexalin Technology Announces UCSD IRB Approval For Use Of HALO Clarity In Clinical Trials For mTBI And PTSD Treatment
Brief: Nexalin Technology Regains Compliance With Nasdaq Continued Listing Requirements
Brief: Nexalin Technology Receives Nasdaq Notice For Minimum Bid Price Non-Compliance
Brief: Nexalin Technology Says Pricing Of $5.2 Million Public Offering
Brief: Nexalin Technology Announces Positive Clinical Study Data In Major Depressive Disorder
Brief: Nexalin Technology Inc Files For Common Stock Offering Of Up To $7.0 Mln
Brief: Nexalin Technology Announces Appointment Of Government Affairs Veteran William A. Hudson, Jr. To Military & Government Advisory Board
Brief: Nexalin Technology Announces Positive Results of Clinical Study Evaluating Its Gen-2 tACS Device
Nexalin rises on positive data for sleep disorder treatment device
Brief: Nexalin Technology Announces Positive Results From Clinical Study Of Gen-2 tACS Device For Treating Adult Patients With Chronic Insomnia
Brief: Nexalin Technology Announces Regulatory Approval In Oman For Gen-2 Neurostimulation Device
Brief: Nexalin Technology Announces Regulatory Approval In Oman For Gen-2 Neurostimulation Device
Brief: Nexalin Technology Inc Says Marilyn Elson Submitted Her Resignation As CFO
Brief: Nexalin Technology Reports Results Of Clinical Study In Treating Migraine Headaches And Related Symptoms
Brief: Nexalin Technology Announces New Public Sector Division